Discovery of small molecule human C5a receptor antagonists
Hitesh J Sanganee1, Andrew Baxter, Simon Barber
1AstraZeneca R&D Charnwood, Medicinal Chemistry, Bakewell Road, Loughborough, LE11 5RH, UK. Hitesh.sanganee@astrazeneca.com
Abstract:
A novel series of small molecule C5a antagonists is reported. In particular, in vitro metabolic studies and solution based combinatorial synthesis are demonstrated as useful tools for the rapid identification of antagonists with low in vitro clearance. Members of this series specifically inhibited the binding of (125)I-labeled C5a to human recombinant C5a receptor (C5aR). In functional cell assays these compounds displayed surmountable antagonism against C5a and did not demonstrate any detectable agonist activity.
More Related Videos
Related Concept Videos
Drug Discovery: Overview
Chemotaxis and Direction of Cell Migration


